Involvement of Dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 730-737

  Pugh Jr , George ^a   Mason Jr , David J ^a   Combs, Vera ^a   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ALPHA NEOENDORPHIN; CANNABINOID; DRONABINOL; DYNORPHIN A; DYNORPHIN B; DYNORPHIN[1-8]; KAPPA OPIATE RECEPTOR; MORPHINE SULFATE; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; INTRATHECAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS; ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; DYNORPHINS; ENDORPHINS; MALE; MICE; MICE, INBRED ICR; RATS; SPINAL CORD;

EID: 8244238393     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. AKIL, H., WATSON, S. J., YOUNG, E., LEWIS, M. E., KHACHATURIAN, H. AND WALKER, J. M.: Endogenous opioids: Biology and function. Annu. Rev. Neurosci. 7: 223-255, 1984.
2. BHARGAVA, H. N.: Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology 49: 267-270, 1976.
3. CHAVKIN, C. AND GOLDSTEIN, A.: Specific receptor for the opioid peptide dynorphin: Structure-activity relationships. Proc. Natl. Acad. Sci. USA 78: 6543-6547, 1981.
4. CHAVKIN, C., JAMES, I. AND GOLDSTEIN, A.: Dynorphin is a specific endogenous ligand for the kappa opioid receptor. Science 215: 413-415, 1982.
5. CLARK, J. A., LIU, L., PRICE, M., HERSH, B., EDELSON, M. AND PASTERNAK, G. W.: Kappa opiate receptor multiplicity: Evidence for two U50,488H-sensitive kappa-1 subtypes and a novel kappa-3 subtype. J. Pharmacol. Exp. Ther. 251: 461-468, 1989.
6. D'AMOUR, F. E. AND SMITH, D. L.: A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72: 74-79, 1941.
7. DEADWYLER, S. A., HAMPSON, R. E., BENNETT, B. A., EDWARDS, T. A., MU, J., PACHECO, M. A., WARD, S. J. AND CHILDERS, S. R.: Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels 1: 121-134, 1993.
8. DEVANE, W. A., HANUS, L., BREUER, A., PERTWEE, R. G., STEVENSON, L. A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. AND MECHOULAM, R.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
9. DEVANE, W. A., SPAIN, J. W., COSCIA, C. J. AND HOWLETT, A. C.: An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J. Neurochem. 46: 1929-1935, 1986.
10. 5]-enkephalin from dynorphin A (1-8) by rat central nervous tissue in vitro. J. Neurochem. 54: 1379-1385, 1990.
11. FUJIMOTO, J. M. AND ARTS, K. S.: Clonidine administered intracerebroventricularly in mice produces an antianalgesic effect which may be mediated spinally by dynorphin A (1-17). Neuropharmacology 29: 351-358, 1990.
12. FUJIMOTO, J. M., ARTS, K. S., RADY, J. J. AND TSENG, L. F.: Spinal dynorphin A (1-17): Possible mediator of antianalgesic action. Neuropharmacology 29: 609-617, 1990.
13. FUJIMOTO, J. M. AND HOLMES, B. B.: Systemic single dose morphine pretreatment desensitizes mice to the spinal antianalgesic action of dynorphin A (1-17). J. Pharmacol. Exp. Ther. 254: 1-7, 1990.
14. GERARD, C. M., MOLLEREAU, C., VASSART, G. AND PARMENTIER, M.: Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res 18: 7142, 1990.
15. GILBERT, P. E.: A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J. Clin. Pharmacol. 21: 311S-319S, 1981.
16. HAN, J. S. AND XIE, C, W.: Dynorphin: Potent analgesic effect in spinal cord of the rat. Life Sci. 31: 1781-1784, 1982.
17. HARRIS, L. S. AND PIERSON, A. K.: Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143: 141-148, 1964.
18. HERKENHAM, M., LYNN, A. B., LITTLE, M. D., JOHNSON, M. R., MELVIN, L. S., DECOSTA, B. R. AND RICE, K. C.: Cannabinoid receptor localization in the brain. Proc. Natl. Acad. Sci. USA 87: 1932-1936, 1990.
19. HOLLT, V.: Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26: 59-77, 1986.
20. HYLDEN J. L. K. AND WILCOX G. L.: Pharmacological characterization of substance P-induced nociception in mice: Modulation by opioid and noradrenergic agonists at the spinal level. Eur. J. Pharmacol. 67: 313-404, 1983.
21. JEN, M. F., LU, C. H., HUANG, L., AND HAN, J. S.: Modulators of pain in the spinal cord. NIDA Monograph Series 75: 457-460, 1986.
22. 1-13, and a kappa-receptor agonist U50,488H. Can. J. Physiol. Pharmacol. 64: 263-268, 1986.
23. LEWIS, M. E., KHACHATURIAN, H. AND WATSON, S. J.: Visualization of opiate receptors and opioid peptides in sequential brain sections. Life Sci 31: 1347-1350, 1982.
24. LITCHFIELD, S. T. AND WILCOXON, F.: A simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113, 1949.
25. LICHTMAN, A. H. AND MARTIN, B. R.: Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258: 517-523, 1991a.
26. 2.noradrenergic mechanism. Brain Res. 559: 309-314, 1991b.
27. MATSUDA, L. A., LOLAIT, S. J., BROWNSTEIN, M. J., YOUNG, A. C. AND BONNER, T. I.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
28. MUNRO, S., THOMAS, K. L., AND ABU-SHAAR, M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
29. NAKAZAWA, T., FURUYA, Y., KANATO, T, AND YAMATSU, K.: Spinal kappa receptor-mediated analgesia of E-2078, a systemically active dynorphin analog, in mice. J. Pharmacol. Exp. Ther. 256: 76-81, 1991.
30. PIERCEY, M. F., VARNER, K. AND SCHROEDER, L. A.: Analgesic activity of intraspinally administered dynorphin and ethylketocyclazocine. Eur. J. Pharmacol. 80: 283-284, 1982.
31. 9-THC-induced antinociception. Brain Res 689: 157-158, 1995.
32. 9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther., in press.
33. PRZEWLOCKA, B., LASON, W. AND DZIEDZICKA, M.: Modulation of prodynorphin peptides release from the rat spinal cord in vitro. Neuropeptides 16: 201-206, 1990.
34. RINALDI-CARMONA, M., BARTH, F., SHIRE, D., MARUANI, J., NELIAT, G., CAPUT, D., SOUBRIE, P., BRELIERE, J. AND LE FUR, G.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350: 240-244, 1994.
35. SHIRE, D., CARILLON, C., KAGHAD, M., CALANDRA, B., RINALDI-CARMONA, M., LEFUR, G., CAPUT, D. AND FERRARA, P.: An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270: 3726-3731, 1995.
36. SLATER, P. AND PATEL, S.: Autoradiographic localization of opiate kappa receptors in rat spinal cord. Eur. J. Pharmacol. 92: 159-160, 1983.
37. 9-tetrahydrocannabinol-induced analgesia. Brain Res. 578: 8-12, 1992.
38. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268: 1381-1386, 1994,
39. SONG, Z. H. AND TAKEMORI, A. E.: Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception. Life Sci. 48: 1447-1453, 1991.
40. SONG, Z. H. AND TAKEMORI, A. E.: Stimulation by CRF of the release of immunoreactive dynorphin A from mouse spinal cords in vitro. Eur. J. Pharmacol. 222: 27-32, 1992.
41. SPAMPINATO, S., ROMUALDI, P., CANDELETTI, S., CAVICCHINI, E. AND FERRI, S.: Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin, and s-calcitonin nociception and motor function in the rat. Pain 35: 94-104, 1988.
42. STEVENS, C. W. AND YAKSH, T. L.: Dynorphin A and related peptides administered intrathecally in the rat: A search for putative kappa receptor activity. J. Pharmacol. Exp. Ther. 238: 833-838, 1986.
43. TSENG, L. L. F.: Intracerebroventricular administration of beta-endorphin releases immunoreactive methionine enkephalin from the spinal cord in cats, guinea pigs and mice. Neuropharmacology 28: 1333-1339, 1989.
44. 9-THC precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280: R13-R15, 1995.
45. 9-tetrahydrocannabinol in rats. Eur. J. Pharmacol. 70: 219-224, 1981.
46. VAYSSE, P. J., GARDNER, E. L. AND ZUKIN, R. S.: Modulation of rat brain opioid receptors by cannabinoids. J. Pharmacol. Exp. Ther. 241: 534-539, 1987.
47. WEBER, E., EVANS, C. J. AND BARCHAS, J. D.: Brain distributions of alpha-neoendorphin: Evidence for regional processing differences. Nature 299: 77-79, 1982.
48. WELCH, S. P.: Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265: 633-640, 1993.
49. WELCH, S. P.: Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol. Biochem. Behav. 49: 929-934, 1994.
50. 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Dep., in press.
51. WELCH, S. P. AND STEVENS, D. L.: Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262: 10-18, 1992.
52. WELCH, S. P., THOMAS, C., AND PATRICK, G. S.: Modulation of cannabinoid-induced antinociception following intracerebroventricular vs. intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272: 310-321, 1995.
53. XIE, C. W., TANG, J., AND HAN, J. S.: Clonidine-stimulated the release of dynorphin in the spinal cord of the rat: A possible mechanism for its depressor effects. Neurosci. Lett. 65: 224-228, 1986.
54. YAKSH, T. L.: The antinociceptive effects of the intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21: 334S-340S, 1981.